The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-08. Anything still debated is marked as such rather than presented as settled.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
The three substrates of this enzyme are (R)-mevalonate, coenzyme A (CoA), and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are (S)-3-hydroxy-3-methylglutaryl-CoA, reduced NADPH, and two protons. This enzyme belongs to the family of oxidoreductases, to be specific those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. This enzyme participates in biosynthesis of steroids including cholesterol. The statin class of anticholesterol drugs act through inhibiting this enzyme.
Immunomodulating agents regulate the immune system's response and are produced by various immune cells. These agents include the following agents and markers: The BCG vaccine has been used against tuberculosis, mycobacteria, and various cancers in the form of vaccination as an initial immune system stimulant. In cancer, the anti-tumor immunological effects are elicited by the host's immune response and the BCG infection against the tumor cells, most commonly in bladder cancer. The immune activation allows for further recognition and elimination of malignant tumor cells. Specific active immunotherapy administers a specific antigen as the therapy. The therapy allows the host to create an antigen-specific response with the development of antibodies, proliferation of cytotoxic T lymphocyte responses, or both, directed at the desired pathogen or malignant tumor cell in the case of cancer therapy.
The primary limitation of SMiLE-seq is that the technique can only be used to characterize the binding interactions of previously identified transcription factors, as the method requires in vitro transcription and translation of the transcription factors prior to their combination with DNA molecules. Additionally, previous studies have shown that fluorescent protein tags can affect the binding affinity of proteins to their targets. The effect of the specific fluorescent protein tags on binding affinity would have to be investigated to determine whether this would impact specific protein-DNA interactions found using this technology. Further development of SMiLE-seq may involve modifying transcription factor expression conditions to increase the success of analysis. SELEX ChIP-seq Protein binding microarrays Competition-ChIP
Serum, suspected to contain IgE antibodies, is drawn from the allergic (atopic) patient. This serum is injected intradermally into a non-allergic person. The suspected antigens are then intradermally injected into the non-allergic person 24–48 hours later. If the person being tested for an allergy has made antibodies for the antigen, this will cause a local reaction in the non-allergic person when the antibodies mix with the antigen. This demonstrates a type I hypersensitivity reaction, and the allergic reaction to the injected antigen is confirmed for the patient being tested. A positive PK test usually appears as a wheal and flare. The test was developed by Otto Prausnitz and Heinz Küstner. The first PK test occurred in 1921 when Prausnitz injected Küstner's serum into his abdominal skin. Küstner had previously noted that he developed allergic symptoms after eating fish. After eating some fish, Prausnitz's skin became hot, red, and swollen at the site of the serum injection, confirming their hypothesis that Küstner was allergic to fish.
Sources: en.wikipedia.org
=== Particle accelerators === The feasibility of technetium-99m production with the 22-MeV-proton bombardment of a molybdenum-100 target in medical cyclotrons following the reaction 100Mo(p,2n)99mTc was demonstrated in 1971. The recent shortages of medical technetium-99m reignited the interest in its production by proton bombardment of isotopically enriched (>99.5%) molybdenum-100 targets. Other techniques are being investigated for obtaining molybdenum-99 from molybdenum-100 via (n,2n) or (γ,n) reactions in particle accelerators.
=== Type 1 diabetes === Insulin degludec was studied as an alternative to insulin glargine as part of a basal-bolus regimen in the BEGIN Basal-Bolus Type 1 trial. 629 participants with type 1 diabetes were randomized in a 3:1 ratio to either insulin degludec (n=472) or insulin glargine (n=157) in addition to mealtime insulin aspart. Participants in the degludec treatment arm were switched from their basal insulin to insulin degludec in a 1:1 ratio, with a 20-30% dose reduction in participants receiving multiple basal doses per day. After 52 weeks, participants treated with insulin degludec produced a similar reduction in HbA1c (0.40% vs. 0.39%) meeting the criteria for noninferiority. Adverse events were similar in the two treatment arms; however, rates of nocturnal hypoglycemia (between midnight and 6am) were 27% lower in participants treated with insulin degludec (3.91 vs. 5.22 episodes per patient-year of exposure, p=0.024). The reduction in the incidence of hypoglycemia was seen as a therapeutic benefit, as hypoglycemia is often a dose limiting toxicity in insulin therapy. A systematic review has compared the use of insulin degludec to that of insulin glargine, insulin detemir and NPH insulin in adults and children diagnosed with type 1 diabetes. This review included Randomized Control Trials (RCTs) with a duration of 24 to 104 weeks and had a total sample of 8784 participants randomized across studies: 2428 participants allocated to NPH insulin; 2889 participants to insulin detemir; 2095 participants to insulin glargine; 1372 participants to insulin degludec.
They further argued, "The use of Russian citizenship to create a “protected” population residing in a neighboring state to undermine its sovereignty is a slippery slope that may lead to a redrawing of the former Soviet borders, including in the Crimea (Ukraine), and possibly in Northern Kazakhstan." Cohen and Hamilton found out that the Baltic intelligence already knew by March 2008 that Russia would attack Georgia in 2008. The authors concluded, "The Russian leadership focused on Georgia as the key element in its strategy to reassert its power in Eurasia." In 2011, Timothy L. Thomas wrote: "An initial catalyst for the confrontation was NATO's April 2008 meeting in Bucharest". Thomas argued: "Russia, some Georgians believed, had given indications that it would not intervene if Georgian troops entered South Ossetia. Unfortunately for Georgia, these "indications" may have been part of Russia's deception plan.
Sources: en.wikipedia.org
=== American IPO and expansion into Europe === In 2001, Reddy's completed its US initial public offering of $132.8 million, secured by American Depositary Receipts. At that time the company also became listed on the New York Stock Exchange. Funds raised from the initial public offering helped Reddy's move into international production and take over technology-based companies. In 2003, Reddy's also invested $5.25 million (USD) in equity capital into Bio Sciences Ltd. Auriegene Discovery Technologies, a contract research company, was established as a fully owned subsidiary of Reddy's in 2002. Auriegene's objective was to gain experience in drug discovery through contract research for other pharmaceutical companies. Reddy's entered into a venture investment agreement with ICICI Bank, an established Indian banking company. Under the terms of the agreement, ICICI Venture agreed to fund the development, registration and legal costs related to the commercialisation of ANDAs on a pre-determined basis. Upon commercialisation of these products, Dr. Reddy's pays ICICI Venture royalty on net sales for a period of 5 years.
==== Gel spinning ==== Gel spinning produces fibers with exceptional strength or other unique qualities. During extrusion, the polymer is not in a pure liquid condition. The polymer chains are linked at different locations in liquid crystal form, partially apart as they would be in a real solution. The resultant filaments have substantial inter-chain forces, which can significantly raise the fiber's tensile strength additionally, the shear forces the liquid crystals to be arranged along the fiber axis during extrusion. Strength is further enhanced by the filaments' exceptionally high degree of alignment as they emerge from one another. Due to the filaments' first air-to-cool cooling phase, the method is known as dry-wet spinning.
=== Events === Japan Tamagokake Gohan Symposium: Held annually in Unnan, Shimane since 2005, originating from the development of the local TKG soy sauce "Otamahan." The symposium discusses the history and appeal of TKG and led to October 30th being designated "Tamagokake Gohan Day." Aspam Tamagokake Gohan Fair: Held in Aomori, Aomori in 2009 at the Aomori Prefecture Tourist Center Aspam. Guinness World Record - Town Revitalization Nippon: In Pippu, Hokkaido, on August 4, 2024, a Guinness World Record was set for the "most people making tamago kake gohan simultaneously." Proposed by local junior high students to promote the town's products (Yumepirika rice, "Kappa no Kenran" eggs, Pippu green onion soy sauce), 325 participants successfully made TKG within 5 minutes.
=== Southeast Asia === The Javanese society of Mataram had gained knowledge of making bean curd (in Old Javanese: tahu) by the time said item was listed among foods served in a ceremonial feast for Balitung off an inscription dated 902 CE, but long after soy beans (kaḍle) were introduced to Javan cultivation by South Indian traders based on morphological comparisons to Indian soy varieties and linguistic evidence.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.